Controlled periods | Cumulative periods | |||||
---|---|---|---|---|---|---|
Outcome | Abatacept: n = 2653; py = 2357 | Placebo: n = 1485; py = 1254 | Abatacept: n = 7044; py = 21,274 | |||
n (%) | IR/100 py (95% CI) | n (%) | IR/100 py (95% CI) | n (%) | IR/100 py (95% CI) | |
Tuberculosis (overall) | 1 (< 0.1) | 0.04 (0–0.2) | 1 (< 0.1) | 0.08 (0–0.4) | 13 (0.2) | 0.06 (0.03–0.10) |
Pulmonary tuberculosis | 0 | 0 | 0 | 0 | 6 (0.1) | 0.03 (0.01–0.06) |
Lymph node tuberculosis | 0 | 0 | 0 | 0 | 2 (< 0.1) | 0.01 (0–0.03) |
Tuberculosis (unspecified) | 1 (< 0.1) | 0.04 (0.0–0.2) | 1 (0.1) | 0.08 (0.0–0.4) | 2 (< 0.1) | 0.01 (0–0.03) |
Bone tuberculosis | 0 | 0 | 0 | 0 | 1 (< 0.1) | 0.01 (0–0.03) |
Peritoneal tuberculosis | 0 | 0 | 0 | 0 | 1 (< 0.1) | 0.01 (0–0.03) |
Tuberculous pleurisy | 0 | 0 | 0 | 0 | 1 (< 0.1) | 0.01 (0–0.03) |
Herpes simplex | 57 (2.1) | 2.5 (1.9–3.2) | 22 (1.5) | 1.8 (1.1–2.7) | 60 (0.9) | 1.48 (1.32–1.65) |
Herpes zoster | 44 (1.7) | 1.9 (1.4–2.5) | 21 (1.4) | 1.7 (1.1–2.6) | 284 (4.0) | 1.53 (1.36–1.71) |
Herpes virus infection (NOS) | 5 (0.2) | 0.2 (0.1–0.5) | 4 (0.3) | 0.3 (0.1–0.8) | 20 (0.3) | 0.09 (0.06–0.15) |